Equity Briefing : Cel-Sci's CEO Kersten sounds bullish on Multikine® Phase III trial progress
(Thomson Reuters ONE) -
In a newly broadcast radio interview with Eric Michaels of the eHealth Radio
Network, Cel-Sci Corporation's (AMEX:CVM) CEO, Geert Kersten hints that Phase
III clinical trials for CEL-SCI's lead investigational therapy, Multikine®
(Leukocyte Interleukin, Injection), an immunotherapeutic agent being developed
as a potential first-line treatment for advanced primary head and neck cancer,
is performing well.
"Our drug essentially replicates a healthy immune system, and based on
everything that we've seen in the clinic so far, if we continue to see the same
results, we will have the first non-toxic cancer therapy, explains Kersten.
"Think about that, that doesn't exist today."
Among some of the topics of interest to investors which were discussed during
the nationally syndicated medical program which can be heard on a number of
public radio and HD Radio stations, including XM channel 123, Kersten is asked
why it has taken decades for this drug cancer treatment candidate to make its
way through the regulatory process and what his vision for the product is at
this point in the clinical testing process.
Kersten also reveals new details about the National Institute of Health's
interest and role in the current trial and says that his firm plans to expand
the trial into additional countries.
"This is the biggest Phase III study ever done in head and neck cancer," Kersten
says. "It is being done in eight countries on three continents and we're
expanding it to twelve countries, and this one study is designed in one fail
swoop to give us approval anywhere and everywhere in the world."
Source: http://bit.ly/MTLNhR
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1622405]
Bereitgestellt von Benutzer: hugin
" alt="Canamex Resources Corp.: Bruner Gold Project in Nye County, Nevada Progressing WellDatum: 27.06.2012 - 14:47 Uhr
Sprache: Deutsch
News-ID 160568
Anzahl Zeichen: 2375
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 296 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Briefing : Cel-Sci's CEO Kersten sounds bullish on Multikine® Phase III trial progress"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
